- Home
- WD vs LXRX Comparison
WD vs LXRX Comparison
Compare WD & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WD | LXRX |
|---|---|---|
| Founded | 1937 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 996.7M |
| IPO Year | 2010 | 2000 |
Fundamental Metrics
Financial Performance| Metric | WD | LXRX |
|---|---|---|
| Price | $34.06 | $1.41 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $48.33 | $4.55 |
| AVG Volume (30 Days) | 527.5K | ★ 2.4M |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | ★ 7.84% | N/A |
| EPS Growth | N/A | ★ 77.78 |
| EPS | ★ 0.55 | N/A |
| Revenue | ★ $1,234,306,000.00 | $49,803,000.00 |
| Revenue This Year | $9.25 | N/A |
| Revenue Next Year | $9.48 | N/A |
| P/E Ratio | $63.17 | ★ N/A |
| Revenue Growth | 8.99 | ★ 60.24 |
| 52 Week Low | $31.40 | $1.10 |
| 52 Week High | $86.32 | $2.68 |
Technical Indicators
Market Signals| Indicator | WD | LXRX |
|---|---|---|
| Relative Strength Index (RSI) | 46.39 | 25.34 |
| Support Level | $31.40 | $1.10 |
| Resistance Level | $52.37 | $1.81 |
| Average True Range (ATR) | 1.55 | 0.08 |
| MACD | 0.41 | -0.01 |
| Stochastic Oscillator | 66.20 | 12.05 |
Price Performance
Historical ComparisonAbout WD Walker & Dunlop Inc
Walker & Dunlop Inc is a United States-based commercial real estate finance company. It is principally engaged in originating, selling, and servicing a number of multifamily and other commercial real estate financing products that are sold under the programs of Freddie Mac, Fannie Mae, Ginnie Mae, and the Federal Housing Administration. The company is managed based on three reportable segments: Capital Markets (CM), Servicing & Asset Management (SAM), and Corporate. The company generates a majority of its total revenue from gains from mortgage banking activities and servicing fees. It conducts business solely in the United States.
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.